Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537779 | 0.74 | PPARG (0.44) | PPARGSMN1; SMN2TP53LMNAMAPT | |
| SCHEMBL13131434 | 0.65 | PPARG (0.43) | PPARGSMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL13168893 | 0.65 | RAB9A (0.49) | PPARGSMN1; SMN2TP53LMNAMAPT | |
| SCHEMBL13145998 | 0.65 | PPARG (0.45) | PPARGSMN1; SMN2TP53LMNAMAPT | |
| SCHEMBL282501 | 0.64 | SMN1; SMN2 (0.47) | PPARGSMN1; SMN2ALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL537640 | 0.64 | PPARG (0.42) | PPARGSMN1; SMN2TP53LMNAMAPT | |
| SCHEMBL14019131 | 0.62 | PPARG (0.51) | PPARGSMN1; SMN2LMNAMAPTRAB9A | |
| SCHEMBL4980053 | 0.61 | KMT2A (0.40) | PPARGSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL900020 | 0.60 | PPARG (0.42) | PPARGSMN1; SMN2LMNAMAPTRAB9A | |
| SCHEMBL11074988 | 0.60 | TRPM8 (0.45) | SMN1; SMN2TP53LMNAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2414359-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | PPARG 206/4885SMN1; SMN2 2524/4885TP53 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.